Institutional Research Archive

Hedge Fund Letters Archive

Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.

Quarter	Letter Date	Fund Name	QTD	YTD	Tickers	Themes	Quick Take

Home Letters Funds Account

TimesSquare Capital Management U.S. FOCUS Growth Equity strategy 2024 Q2 Investor Letter | Buyside Digest

Back to Fund Profile (TimesSquare Capital Management U.S. FOCUS Growth Equity strategy)

Primary Source Intelligence • Q2 2024 Letter Analysis

TimesSquare Capital Management U.S. FOCUS Growth Equity strategy Quarterly Analysis

Buyside Digest is not affiliated with, and does not endorse, TimesSquare Capital Management U.S. FOCUS Growth Equity strategy. This analysis is provided for institutional research purposes only and is not investment advice.

Fund Returns

QTD+0%

Annualized+23.36%

Positioning StanceConstructive

Market CapMid Cap

GeographyUS

Digest Analysis

Quick Take

"TimesSquare's concentrated mid-cap growth strategy outperformed in Q2 through strong cybersecurity and semiconductor positions, offsetting biotech weakness from regulatory concerns."

Executive Summary

TimesSquare Capital Management's U.S. FOCUS Growth Strategy outperformed the Russell Midcap Growth Index in Q2 2024 despite a challenging market environment dominated by the Magnificent Seven. The concentrated portfolio benefited from strong cybersecurity holdings, with CrowdStrike gaining 20% on 33% annual recurring revenue growth and Palo Alto Networks returning 19% through platform contract emphasis. Teradyne surged 31% as semiconductor testing equipment demand recovered, particularly for high-bandwidth memory chips. However, the portfolio faced headwinds from Legend Biotech's 27% decline due to BIOSECURE Act concerns, leading to position removal, and weakness in Veeva Systems and Chemed Corporation amid broader consumer spending pressures. The investment team observes tight consumer spending affecting retail and industrial sectors, while technology spending remains muted despite GenAI headlines. Data center capex remains strong with cloud spending projected 40% higher in 2024. The managers continue seeking businesses approaching positive inflection points or with sustained growth trajectories, maintaining their bottom-up fundamental approach in an environment where many companies project late-2024 rebounds.

Unlock Full Institutional Analysis

Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.

Sign In to Unlock (3 Free Credits)View Pricing Tiers

Institutional Meta Strategy

Meta Strategy Gauges

Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.

Signal Matrix

Market Conviction

72%

CautiousHigh

High Conviction (72%)

The fund maintains a concentrated portfolio of approximately 15 stocks with detailed thesis explanations for each holding. Specific position sizing actions are described (removing Legend Biotech, trimming Chemed), and the manager provides clear rationale for holdings. The concentrated nature and willingness to make decisive portfolio changes reflects high conviction, though not at the extreme end.

Growth Outlook

25%

BearishBullish

Bearish (25%)

The manager acknowledges challenging market conditions with tight consumer spending and muted IT spending, but also notes positive trends in data centers and expects company rebounds later in 2024. The outlook is cautiously constructive but acknowledges meaningful headwinds.

Risk Appetite

10%

DefensiveAggressive

Defensive (10%)

The portfolio removed a position (Legend Biotech) due to regulatory risk and trimmed another (Chemed) due to weakness. This indicates a selective, risk-aware approach rather than aggressive risk-taking, though they maintain concentrated positions in growth names.

Capital Deployment

43%

De-riskingDeploying

Net Neutral (43%)

The portfolio removed one position entirely (Legend Biotech) and trimmed another (Chemed), indicating net capital reduction rather than deployment. While no cash levels are provided, the described actions suggest modest de-risking rather than aggressive deployment.

Forward Guidance

30%

CautiousExpansionary

Cautious (30%)

The manager continues seeking businesses with positive inflection points and growth trajectories, indicating a selective deployment bias. They express confidence in their bottom-up approach and note many companies project rebounds later in 2024.

Language Signal

15%

BearishBullish

Bearish (15%)

Language is balanced with both positive developments (cybersecurity strength, data center growth) and negative factors (consumer spending pressures, regulatory risks). Slightly more cautious than bullish overall with emphasis on selectivity and risk management.

Perceived Risk

65%

Low RiskElevated

Elevated Risk (65%)

The manager identifies multiple specific risks including tight consumer spending, muted IT spending, regulatory risks (BIOSECURE Act), and disappointing industrial forecasts. These risks are discussed in detail with concrete examples and portfolio implications, indicating meaningful risk awareness.

Opportunity Density

45%

ScarceAbundant

Selective (45%)

The manager sees selective opportunities in specific areas like cybersecurity and semiconductor recovery, but also notes challenging conditions in consumer and industrial sectors. The emphasis on seeking businesses with positive inflection points suggests opportunities exist but require careful selection.

Time Horizon

70%

Short-TermLong-Term

Decade+ (70%)

The fund describes a fundamental research-driven approach looking for businesses with sustained growth trajectories and positive inflection points. The willingness to hold through volatility (as with Veeva Systems CFO transition) and focus on long-term fundamentals indicates a multi-year investment horizon, though some catalyst dependency is evident.